BK0066 Processing of Agricultural Products
- 981.364
- +9.766+1.01%
Research Report: Guoxin Securities: Arowana's diversified development is worth looking forward to, maintaining a “buy” rating
Arowana (300999): Double increase in kitchen food volume and profit in 2024Q1, net profit to mother +3.30% YoY
Chenguang Biotech (300138): Increased repurchase efforts to 400 million yuan
Daodaoquan (002852) 23 Annual Report and '24 Quarterly Report Review: Significant improvement in sales volume, launch of a wide range of flavoring oils
Review of COFCO Sugar's (600737) Annual Report and '24 Quarterly Report: High Performance Delivers High Dividends and Continues High Prosperity for a Long Period
Arowana (300999) Company Incident Review Report: Low Prices Drag Down Revenue and Increase in Profitability of Core Products
Chenguang Biotech (300138): Performance falls short of forecast, the central plant extraction business performed steadily
Southwest Securities released a research report on April 23 stating that it gave Chenguang Biotech (300138.SZ) a purchase rating. The main reasons for the rating include: 1) the vegetable extraction business consolidates advantages, and the echelon produc
Chenguang Biotech (300138): Steady growth in plant extraction business revenue and pressure on profitability
Zuming Co., Ltd. (003030): Dual incentives are sufficient, and regional expansion is progressing in an orderly manner
Zuming Co., Ltd. (003030): Focus on regional expansion and channel transformation, the dual incentives show confidence
Chenguang Biotech (300138): Continued consolidation of main business advantages and multi-product collaboration
Sorobao Protein (603231): The world's leading producer of vegetable protein is growing rapidly overseas & direct sales
Arowana (300999): Lower prices led to a decline in revenue and an improvement in the profit of feed ingredients
Arowana (300999): Sales growth & price pressure, the company's performance declined slightly in 23 years
Research Report Nuggets丨Huaxin Securities: Arowana's performance is under slight pressure. It is optimistic about the subsequent release of flexibility and maintains a “buy” rating
Arowana (300999): Short-term performance is under pressure, and the release of profit elasticity can be expected
Research Report Nuggets丨Huaxin Securities: Chenguang Biotech Continues to Release Performance Flexibility and Maintain a “Buy” Rating
Chenguang Biotech (300138) Company Incident Review Report: Performance is in line with expectations, stable product release at various levels
Chenguang Biotech (300138): Repurchases continue to increase, and value is significantly undervalued